Bolt Biotherapeutics, Inc.
BOLTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 20, 2025 | H.C. Wainwright | $7.00(+22%) | $5.75 | TheFly | |
| May 15, 2024 | Leerink Partners | Daina Graybosch | $1.00(-24%) | $1.32 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | May 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2026 |
| Lake Street | maintain | Buy | Aug 15, 2025 |
| Stifel | maintain | Hold | May 13, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 25, 2025 |
| Stifel | maintain | Hold | Mar 25, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 15, 2024 |
| Stifel | downgrade | Buy →Hold | May 15, 2024 |
| Leerink Partners | downgrade | Outperform →Market Perform | May 15, 2024 |
| Jones Trading | downgrade | Buy →Hold | May 15, 2024 |
| Guggenheim | downgrade | Buy →Neutral | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 26, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2023 |
| SVB Leerink | upgrade | Market Perform →Outperform | May 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2023 |
| Morgan Stanley | maintain | Equal Weight | Jan 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 4, 2022 |
| SVB Leerink | downgrade | Outperform →Market Perform | Aug 11, 2022 |
| Morgan Stanley | maintain | Equal Weight | May 17, 2022 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Jan 6, 2022 |
| SVB Leerink | maintain | Outperform | Nov 10, 2021 |
| SVB Leerink | maintain | Outperform | Aug 16, 2021 |
Earnings History
Next report: Mar 31, 2027 · EPS est. $-3.85| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-4.57 | $-3.39 | $5.0K | $500.0K |
| May 12, 2026 | $-4.31 | $-2.85 | $26.0K | $1.5M |
| Mar 12, 2026 | $-3.84 | $-4.30 | $2.5M | $666.7K |
| Nov 12, 2025 | $-3.72 | $-5.07 | $2.2M | $820.8K |
| Aug 14, 2025 | $-4.46 | $-6.40 | $1.8M | $819.8K |
| May 12, 2025 | $-5.80 | $-6.80 | $1.2M | $757.3K |
| Mar 24, 2025 | $-7.60 | $-7.60 | $10.0K | $775.7K |
| Nov 12, 2024 | $-8.00 | $-6.80 | $1.1M | $1.3M |
News
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered on the 47th floor in the Empire State Building in New York City and are investigating if below deal is fair:
/PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences.
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) related to its merger with Prana Therapies, Inc. Is it a fair deal?
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its propr…
Shares of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.20 and traded as high as $4.48. Bolt Biotherapeutics shares last traded at $4.14, with a volume of 34,467 shares trading hands. Wall
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.23 and traded as low as $3.45. Bolt Biotherapeutics shares last traded at $3.53, with a volume of 23,259 shares changing hands. Wall Street Analyst Weigh In Separately,
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) VP Sarah Nemec sold 4,077 shares of Bolt Biotherapeutics stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a total value of $13,209.48. Following the completion of the transaction, the vice president owned 17,082 shares of the
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) COO Grant Yonehiro sold 4,909 shares of the firm's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $3.32, for a total transaction of $16,297.88. Following the completion of the transaction, the chief operating officer directly owned
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second…